David Liew

In this conversation, rheumatology advanced trainee Steph Hopkins and rheumatologist David Liew delve into the critical aspects of selecting nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management. They explore the balance between risks and benefits, discussing the profiles of various NSAIDs in relation to conditions like osteoarthritis and cardiovascular risks. The duo also highlights the importance of considering individual patient needs, such as co-prescribing PPIs and addressing specific risks during pregnancy or for patients with renal issues.

David Liew, a renowned rheumatologist from Melbourne, joins an expert panel to discuss groundbreaking findings from the ACR Annual Meeting. They explore the effectiveness of Upadacitinib for treating giant cell arteritis and the complexities surrounding patient enrollment for trials. The conversation shifts to the skepticism around methotrexate for polymyalgia rheumatica and the potential of JAK inhibitors in myositis. Safety concerns regarding these therapies, particularly in cardiovascular health, underscore the importance of ongoing research.

Join Dr. David Liew, a renowned rheumatologist, as he dives into the role of JAK inhibitors in treating polymyalgia rheumatica. He discusses the recent breakthroughs that are reshaping treatment strategies and making these therapies more accessible. The conversation also turns to the cardiovascular risks associated with JAK inhibitors, compared to traditional steroid use. Liew's insights highlight the importance of evaluating both benefits and risks in personalized rheumatology care.